Quality of life and cost‐effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG ‐naïve non‐muscle‐invasive bladder cancer
BJU International · 2026
DOI: 10.1111/bju.70126 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift BJU International, 2026. Verfasst von Aviral Srivastava und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Deoxycytidine, Quality of Life, BCG Vaccine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Objective
To compare intravesical gemcitabine/docetaxel (Gem/Doce) vs standard‐of‐care bacillus Calmette–Guérin (BCG) in intermediate‐/high‐risk non‐muscle‐invasive bladder cancer (NMIBC), as patient‐reported physical‐psychological quality of life (QoL) and cost‐effectiveness estimation are pivotal to evaluate adjuvant intravesical treatments yet are rarely evaluated head‐on. Patients and Methods In a prospective per‐protocol analysis (Gem/Doce 39 patients; BCG 44 patients), survival endpoints (recurrence‐free survival [RFS], progression‐free survival [PFS]) and National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)‐graded adverse events (AEs) were recorded. QoL was assessed at baseline, post‐induction, and at 6 and 12 months using the European Organisation for Research and Treatment of Cancer Quality‐of‐Life Questionnaire‐30‐item core (EORTC QLQ‐C30) and 24‐item QLQ‐NMIBC (QLQ‐NMIBC24) and mapped to the EuroQoL five Dimensions five Levels (EQ‐5D‐5L) using an Indian tariff to estimate quality‐adjusted life years (QALYs). Direct medical costs were recorded, and incremental cost‐effectiveness ratios (ICERs) were calculated per QALY and recurrence/progression outcomes.
Results
Patients receiving Gem/Doce achieved higher 1‐year RFS (94.74% vs 75%, hazard ratio 0.44; P = 0.02) and PFS (100.00% vs 93.19%, P = 0.09). The AEs were fewer with Gem/Doce (12.82% vs 34.10%, P = 0.028); Grade 3 events occurred only with BCG (4.65%). Gem/Doce showed significantly higher global health, physical/role/emotional functioning and sexual health scores at 6–12 months, with reduced fatigue, urinary symptoms and intravesical‐treatment problems. Mean QALYs improved with Gem/Doce (0.8807 vs 0.7198), and with an ICER of ₹504 000 Indian Rupees ($6072 United States Dollars) per QALY – well within India's willingness‐to‐pay threshold and far below international benchmarks. Additional gains included +1.38 recurrence‐free months overall and +2.82 in high‐risk patients, achieved at acceptable incremental cost, indicating pragmatic cost profile against avoided recurrences and QoL gains.
Conclusions
Sequential Gem/Doce delivered optimal short‐term survival outcomes, favourable patient‐reported QoL and safety profile, and attractive cost per avoided recurrence/progression compared with BCG, supporting its adoption as a clinically and economically viable alternative in resource‐constrained NMIBC care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
ORCID-Profile: Aviral Srivastava, Sameer Trivedi, Yashasvi Singh
Zitieren
APA
Srivastava, A., Trivedi, S., Kumar, U., Singh, Y., Kumar, L., Data, S., Kumar, A., & Sankhwar, S. N. (2026). Quality of life and cost‐effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG ‐naïve non‐muscle‐invasive bladder cancer. BJU International. https://doi.org/10.1111/bju.70126
Vancouver
Srivastava A, Trivedi S, Kumar U, Singh Y, Kumar L, Data S, et al. Quality of life and cost‐effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG ‐naïve non‐muscle‐invasive bladder cancer. BJU International. 2026. doi:10.1111/bju.70126
BibTeX
@article{Srivastava2026,
author = {Srivastava, Aviral and Trivedi, Sameer and Kumar, Ujwal and Singh, Yashasvi and Kumar, Lalit and Data, Sahil and Kumar, Anil and Sankhwar, Satya Narayan},
title = {Quality of life and cost‐effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG ‐naïve non‐muscle‐invasive bladder cancer},
journal = {BJU International},
year = {2026},
doi = {10.1111/bju.70126}
}
EUVIMED